Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

1
(No Transcript)
2
Sglt-2 insulin

• Matthews D, Fulcher G, Perkovic V, et al. Ef?cacy
  and safety of canagliflozin,an inhibitor of
  sodium glucose co-transporter 2, added on to
  insulin therapy with or without oral agents in
  type 2 diabetes. Poster presented at The 48th
  Annual Meeting of the European Association for
  the Study of Diabetes (EASD),October 1-5, 2012,
  Berlin, Germany.
• Janssen Research Development, LLC. (Posted
  2009). CANVAS- CANagli?ozin cardioVascular
  Assessment Study (NCT01032629).http//www.clinical
  trials.gov/ct2/show/NCT01032629 (Accessed 15 Jan
  2013).
• Rosenstock J, Davies M, Dumas R, et al. Effects
  of canagli?ozin added onto basal insulin with or
  without other antihyperglycemic agents in type 2
  diabetes. Poster presented at The 73rd Scienti?c
  Sessions of the American Diabetes Association
  (ADA), June 21-25, 2013, Chicago, IL.

3
Canvas SGLT-2 Basal /bolus /- other agents
Mathews
4
(No Transcript)
5
(No Transcript)
6
Dapa insulin- insulin sparing

• 4.3.4 Placebo-Controlled Trial of
• Insulin-Sparing Effect
• In patients with type 2 diabetes who had
• inadequate glycaemic control despite high-dose
• insulin plus oral antidiabetic drugs that act
• via insulin-dependent mechanisms (metformin,
  pioglitazone or rosiglitazone), the addition of
• dapagliflozin 10 or 20 mg/ day, after halving the
• insulin dosage at baseline, was associated with
• more favourable effects on HbA1c , FPG, PPG
• and body weight than placebo in a 12-week,
• randomized, double-blind trial.43 A total of
  71
• patients were randomized in a 1 1 1 ratio to
  the
• three treatment groups, and statistical analyses
• were not reported. For the primary endpoint of
• mean change from baseline in HbA1c at week 12,
• results for dapagliflozin 10 mg/ day, 20 mg/ day
• and placebo were - 0.61 , - 0.69 and 0.09 ,
• respectively.

Wilding JPH, Norwood P, TJoen C, et al. A study
of dapagliflozin in patients with type 2 diabetes
receiving high doses of insulin plus insulin
sensitizers applicability of a novel
insulin-independent treatment. Diabetes Care
2009 Sep 32 (9) 1656-62
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
(No Transcript)